Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dietary Geraniol by Oral or Enema Administration Strongly Reduces Dysbiosis and Systemic Inflammation in Dextran Sulfate Sodium-Treated Mice

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      De Fazio L; Spisni E; Cavazza E; Strillacci A; Candela M; Centanni M; Ricci C; Rizzello F; Campieri M; Valerii Mc
    • Publication Date:
      2016
    • Collection:
      Università degli Studi di Brescia: OPENBS - Open Archive UniBS
    • Abstract:
      Trans)-3,7-Dimethyl-2,6-octadien-1-ol, commonly called geraniol (Ge-OH), is an acyclic monoterpene alcohol with well-known anti-inflammatory, antitumoral, and antimicrobial properties. It is widely used as a preservative in the food industry and as an antimicrobial agent in animal farming. The present study investigated the role of Ge-OH as an anti-inflammatory and anti-dysbiotic agent in the dextran sulfate sodium (DSS)-induced colitis mouse model. Ge-OH was orally administered to C57BL/6 mice at daily doses of 30 and 120 mg kg(−1) body weight, starting 6 days before DSS treatment and ending the day after DSS removal. Furthermore, Ge-OH 120 mg kg(−1) dose body weight was administered via enema during the acute phase of colitis to facilitate its on-site action. The results show that orally or enema-administered Ge-OH is a powerful antimicrobial agent able to prevent colitis-associated dysbiosis and decrease the inflammatory systemic profile of colitic mice. As a whole, Ge-OH strongly improved the clinical signs of colitis and significantly reduced cyclooxygenase-2 (COX-2) expression in colonocytes and in the gut wall. Ge-OH could be a powerful drug for the treatment of intestinal inflammation and dysbiosis
    • File Description:
      ELETTRONICO
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/26973525; volume:7; firstpage:1; lastpage:11; numberofpages:11; journal:FRONTIERS IN PHARMACOLOGY; https://hdl.handle.net/11379/558116
    • Accession Number:
      10.3389/fphar.2016.00038
    • Online Access:
      https://hdl.handle.net/11379/558116
      https://doi.org/10.3389/fphar.2016.00038
    • Rights:
      info:eu-repo/semantics/openAccess
    • Accession Number:
      edsbas.CCE3C84E